* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download CNS 2 anxiolytics
Drug interaction wikipedia , lookup
Cannabinoid receptor antagonist wikipedia , lookup
Nicotinic agonist wikipedia , lookup
Discovery and development of antiandrogens wikipedia , lookup
5-HT3 antagonist wikipedia , lookup
Discovery and development of angiotensin receptor blockers wikipedia , lookup
Effects of long-term benzodiazepine use wikipedia , lookup
Toxicodynamics wikipedia , lookup
Polysubstance dependence wikipedia , lookup
NK1 receptor antagonist wikipedia , lookup
Neuropharmacology wikipedia , lookup
CNS DEPRESSANTS Anti-Anxiety Agents and Sedative-Hypnotics 1 INTRODUCTION • Anxiety is an unpleasant state of tension, apprehension or uneasiness from an unknown source. • Symptoms are similar to those of fear and is due to sympathetic activation • Symptoms of Chronic, severe, debilitating anxiety requires treatment • Hypnosis simply means sleep inducing • All antianxiety drugs cause sedation, and can also function as anxiolytic and hypnotic agents. 2 • A sedative drug decreases activity, moderates excitement, and calms the recipient. • B. A hypnotic drug produces drowsiness and facilitates the onset and maintenance of a state of sleep that resembles natural sleep, and from which the patient can be easily aroused. • C. An anxiolytic drug reduces anxiety. 3 4 CLASSIFICATION • Barbiturates • Benzodiazepines • Are the two major categories of sedativehypnotics • Other anxiolytic drugs • Nonbarbiturate sedatives 5 BENZODIAZEPINES (BDZs) • Are the most widely used anxiolytic drugs • Have replaced barbiturates in the treatment of anxiety cos are more effective and safer. 6 Mech of action • GABA-A receptors is the target for BDZs. • It binds to a site on GABA-A called BDZ receptors • Binding of GABA to its receptor opens the chloride channel causing hyperpolarization. • MOA: binding of BDZs to a site on GABA-A receptor potentiates the effect of GABA by ↑ing the frequency of opening of chloride channel. 7 8 Benzodiazepines • • • • • • • • • • DIAZEPAM ALPRAZOLAM LORAZEPAM CLONAZEPAM FLURAZEPAM TEMAZEPAM QUAZEPAM MIDAZOLAM ESTAZOLAM TRIAZOLAM 9 ACTIONS • Reduction of anxiety: at low doses and acts via enhancing the effects of GABA by binding to GABA-A receptors. • Sedative and hypnotic: at higher doses via binding to GABA-A and enhancing the effect of GABA • Anterograde amnesia: causes temporary impairment of memory by binding to GABA-A receptors. • Anticonvulsant: used to treat epilepsy 10 • • Muscle relaxant: at high doses • All BDZs have neither anesthetic nor analgesic property 11 Therapeutic uses • Anxiety disorders: that accompanies depression and schizophrenia. • Panic disorder, phobias: alprazolam • Muscular disorder: diazepam • Amnesia • Seizures: clonazepam, diazepam(grand mal and status epilepticus) • Clorazepate, chlordiazepoxide, diazepam, oxazepam and lorazepam useful for treatment 12 of alcohol withdrawal continuation • Sleep disorders: • Flurazepam: ↑es duration of sleep, ↓es number of awakenings and its long acting • Temazepam: used in pts who experience freq wakening • Triazolam: used to induce sleep in pts with insomnia. 13 PHARMACOKINETICS • BDZs are rapidly and completely absorbed after oral administration. • Duration of action: • Long acting BDZs (1-3days):clorazepate, chlordiazepoxide, diazepam, flurazepam and quazepam • Intermediate acting(10-20 hours): alprazolam, estazolam, lorazepam, temazepam • Short-acting (3-8 hours): oxazepam, triazolam 14 Fate of BDZs • Most are metabolized by the hepatic P450 system to compunds that are also active. • Their effects are terminated by excretion or redistribution. • All BDZs cross the placenta 15 PRECAUTIONS • LIVER FAILURE (most BDZs). • Some are not metabolized by the liver and so can be given to pts with liver disease. It includes Oxazepam, Temazepam, Lorazepam. These drugs are not metabolized in liver. ( remember the first letters OTL – Outside The Liver) • Alcohol and other CNS depressants enhance the sedative-hypnotic effects of BDZs • Should be avoided in pts with narrow angle glaucoma 16 ADVERSE EFFECTS • DROWSINESS, CONFUSION • ATAXIA • Cognitive impairment • DEPENDENCE : PSYCHOLOGICAL, PHYSICAL WITHDRAWAL : • ANXIETY, TENSION,CONFUSION, restlessness, REBOUND INSOMNIA (Triazolam) 17 Benzodiazepine antagonist FLUMAZENIL • GABA receptor antagonist • Rapidly Reverses the effect of benzodiazepines. • I.V. route only. • Used for treatment of BDZs poisoning SE: • Nausea, vomiting, agitation and dizziness. 18 OTHER ANXIOLYTIC DRUGS • BUSPIRONE • HYDROXYZINE • ZOLPIDEM • ZALEPLON 19 OTHER ANXIOLYTICS - BUSPIRONE • Site of action: binds to 5-HT1A receptor subtype. • No anticonvulsant activity. • No interaction with benzodiazepine binding sites • No muscle relaxant properties and causes minimal sedation • Minimal adverse effects • USED FOR GAD Generalized Anxiety Disorders • Slow onset of action 20 ZOLPIDEM • ACTS ON BENZODIAZEPINE RECEPTORS though not a BDZ. • HYPNOTIC • NO ANTI CONVULSANT • NO MUSCLE RELAXTION • MINIMAL REBOUND INSOMNIA • • • • ONSET OF ACTION – FAST METABOLIZED BY P450 TO INACTIVE COMPOUND HALF LIFE – SHORT ( 3 HOURS) SE: NIGHTMARES, GI UPSET, DAYTIME DROWSINESS 21 ZALEPLON • Similar to zolpidem in its hypnotic actions but causes fewer side effects compared to zolpidem or BDZs. • Has a half life of < 1hour • Metabolized by cyt P450 system. 22 Barbiturates • Were formerly the mainstay of treatment used to sedate the patient or to induce and maintain sleep. • Have been replaced by BDZs cos they induce tolerance, physical dependence, severe withdrawal symptoms and coma in toxic doses. 23 DRUGS • • • • • PHENOBARBITAL – LONG ACTING PENTOBARBITAL SECOBARBITAL Both are short acting THIOPENTAL – ULTRA SHORT ACTING ( 20 MIN) 24 BARBITURATES MECH OF ACTION : • Bind to GABA-A receptors potentiating the effect of GABA by prolonging the duration of chloride channel opening. 25 Actions • Anesthesia • Treatment of seizures • Sedative(low dose) and hypnotic agents(high doses) • Depression of CNS and can lead to coma and death. • Respiratory depression • Induces P450 in the liver 26 • No analgesic action Therapeutic uses • Anesthesia: thiopental an ultra-short acting barbiturate is used intravenously to induce anesthesia. • Anticonvulsant: phenobarbital used in the long term management of tonic-clonic seizures, status epilepticus • Anxiety: used as sedatives to relieve anxiety, nervous tension, insomnia at low doses 27 pharmacokinetics • Readily cross the placenta and can depress the fetus. • Are metabolized by the liver except phenobarbital • Excreted in urine • Barbiturate + alcohol = bad combination 28 ADVERSE EFFECTS • Drowsiness • CNS: Impaired concentration, sluggishness • HANG OVER: Hynoptic doses • METABOLISED IN LIVER • CI : ACUTE INTERMITTENT PORPHYRIA • DEPENDENCE: • WITHDRAWAL SEVERE: MAY CAUSE DEATH29 Barbiturate poisoning • • • • Severe depression of respiration CVS depression Shock Treatment: artificial respiration,gastic lavage, hemodialysis, alkalinzation of urine. • No specific barbiturate antagonist available 30 NONBARBITURATE SEDATIVES • Chloral hydrate • Antihistamine • ethanol 31 OTHER SEDATIVES • ANTIHISTAMINES : diphenhydramine, doxylamine are effective in treating mild types of insomnia CHLORAL HYDRATE • SEDATIVE AND HYPNOTIC • SE: GI UPSET • TASTE CHANGES • PREFERRED ROUTE : PER RECTAL 32 33 ETHANOL • • • • • • Is a CNS depressant at high doses Anxiolytic Produces sedation Hypnosis with increasing dosage. Crosses the placenta Metabolized in the liver first to acetaldehyde by alcohol dehydrogenase and then to acetate by acetaldehyde dehydrogenase 34 ALCOHOL METAB 35 CNS CHR. EFFECT • DEPRESSION, MEMORY LOSS • RISK FOR SEIZURES • WERNICKES – KORSAKOFFS ENCEPHALOPATHY • Metabolic effects: hypoglycemia, gout, lactic acidosis 36 CVS : • ACUTE : VASODILATION • HIGH DOSES : VASOCONSTRICTION IN HEART • CHRONIC: MYOCARDIAL DEPRESSION GIT : • ACUTE : STIMULATES ACID • HIGH : DIRECT IRRITATION • CHRONIC: DIARRHOEA / CONSTIPATION,, PANCREATITIS 37 • LIVER : • CHR : CIRRHOSIS • RESPIRATORY DEPRESSION • CHRONIC :IMPOTENCE, TESTICULAR ATROPHY, GYNAECOMASTIA • PREGNANCY : FETAL ALCOHOL SYN. • LOW IQ, MICROCEPHALY, FACIAL ABNORMAILITIES. 38 39 continuation • Elimination: kidney(MC), lung • Alcohol withdrawal is treated with BDZs 40 Disulfiram • Blocks the oxidation of acetaldehyde to acetate by inhibiting acetaldehyde dehydrogenase • Results in the accum of acetaldehyde in the blood causing unpleasant symptoms such as flushing, tachycardia, hyperventilation, nausea • Used in pts seriously desiring to stop alcohol ingestion. 41 OTHER ALCOHOLS METHANOL : • FORMS FORMIC ACID • EFFECTS : BLINDNESS, SEVERE ACIDOSIS.. Respiratory failure… • Ethylene glycol: forms OXALIC ACID • Side effect: acute tubular necrosis, CNS depression, acidosis 42 43 Treatment for overdose • Fomepizole: long acting inhibitor of alcohol dehydrogenase • IV Ethanol: for methanol and ethylene glycol poisoning 44